Distribution of serum amylase levels in patients with cutaneous leishmaniasis treated with meglumina antimoniate
The treatment of choice for leishmaniasis is meglumine antimoniate, reporting effects at the pancreatic duct. A study with 90 patients between August 2010 and April 2011 found amylase changes at the beginning, middle and end of treatment at doses of 20 mg/kg/ day. The averages were: weight, 68 kg±9....
| Autor Principal: | Rodríguez, Ángela Johanna; Clínica Meta |
|---|---|
| Otros Autores: | Macías, Eva Lucía; Hospital Militar de Oriente |
| Formato: | info:eu-repo/semantics/article |
| Idioma: | spa |
| Publicado: |
Pontificia Universidad Javeriana
2016
|
| Materias: | |
| Acceso en línea: |
http://revistas.javeriana.edu.co/index.php/vnimedica/article/view/16118 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: |
The treatment of choice for leishmaniasis is meglumine antimoniate, reporting effects at the pancreatic duct. A study with 90 patients between August 2010 and April 2011 found amylase changes at the beginning, middle and end of treatment at doses of 20 mg/kg/ day. The averages were: weight, 68 kg±9.1, age 24.73±4.45 years, and 28.15±3.97 g of the drug dose. The site of injury was 44,4% in upper limbs. No significant association was found between the variables weight, age and treatment programs. Alteration was present in 49,37% in the middle of treatment and 6,5% at the end. There were significant differences in reported half-amylase treatment on the two doses (p=0.000). In conclusion, control must be performed in serum amylase and rising especially in the middle of treatment. |
|---|